Description
SWOT ANALYSIS OF DR. REDDY'S LABORETORIES LIMITED
Dr.Reddy's Laboratories Ltd
Parent Company
Dr.Reddy's Laboratories Ltd
Category
Pharmaceuticals
Sector
Health care
Tagline/ Slogan
Life. Research. Hope
Strong vertically integrated portfolio of products, businesses & USP geographies
STP
Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical Services (CPS), generics, biosimiler, differentiated formulations and Segment News Chemical Entities (NCEs)
Target Group
Healthcare professionals, retail outlets
Committed to providing affordable and innovative medicines for Positioning healthier lives
SWOT Analysis
1. Company launched Peg-grafeelTM, an inexpensive variety of pegfilgrastim, used to fight infection in chemotherapy where company has sold some 1.5 million units of it. 2. Dowpharma/Chirotech acquisition provided proprietary chiral and biocatalysis technology 3.The acquisition of Beta pharma helped to introduce an array of generic products and show its presence in the European markets. Strength 4. Has a strong workforce of over 15,000 employees
1. Discovery of drugs is a highly unpredictable business Weakness 2. Strict govt regulations and policies affects operational efficiency
1. Leverage Biologics & Cytotoxic Infrastructure to deal with the need of Oncology Market 2.New partnerships to develop Biosimiler business 3. Develop cost effective ways of new drug development to improve Opportunity business in emerging markets
Threats
1.Preliminary investment for Drug discovery is very high
2. long gestational period for new drug development 3. increasingly stringent regulations for new drug development
Competition
1. Sun pharma 2. Lupin 3. Cipla Competitors 4. Ranbaxy labs
doc_631121577.docx
SWOT ANALYSIS OF DR. REDDY'S LABORETORIES LIMITED
Dr.Reddy's Laboratories Ltd
Parent Company
Dr.Reddy's Laboratories Ltd
Category
Pharmaceuticals
Sector
Health care
Tagline/ Slogan
Life. Research. Hope
Strong vertically integrated portfolio of products, businesses & USP geographies
STP
Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical Services (CPS), generics, biosimiler, differentiated formulations and Segment News Chemical Entities (NCEs)
Target Group
Healthcare professionals, retail outlets
Committed to providing affordable and innovative medicines for Positioning healthier lives
SWOT Analysis
1. Company launched Peg-grafeelTM, an inexpensive variety of pegfilgrastim, used to fight infection in chemotherapy where company has sold some 1.5 million units of it. 2. Dowpharma/Chirotech acquisition provided proprietary chiral and biocatalysis technology 3.The acquisition of Beta pharma helped to introduce an array of generic products and show its presence in the European markets. Strength 4. Has a strong workforce of over 15,000 employees
1. Discovery of drugs is a highly unpredictable business Weakness 2. Strict govt regulations and policies affects operational efficiency
1. Leverage Biologics & Cytotoxic Infrastructure to deal with the need of Oncology Market 2.New partnerships to develop Biosimiler business 3. Develop cost effective ways of new drug development to improve Opportunity business in emerging markets
Threats
1.Preliminary investment for Drug discovery is very high
2. long gestational period for new drug development 3. increasingly stringent regulations for new drug development
Competition
1. Sun pharma 2. Lupin 3. Cipla Competitors 4. Ranbaxy labs
doc_631121577.docx